drugset / Trial / NCT05875610
Preventive Approach Using Venlafaxine
RandomizedParallel-groupOpen-labelTreatment
Summary
Peripheral and Motor neuropathy represent a main obstacle for a better quality of life for cancer patients, Venlafaxine is introduced in a new dosing regimen for treating of oxaliplatin and taxanes induced peripheral neuropathy in cancer patients.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2023-10-01
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gabapentin | Small molecule | 400 mg | — |
| Subject | Venlafaxine | Small molecule | 75 mg | — |